Safety and efficacy of doxycycline in the treatment of rosacea

Clinical, Cosmetic and Investigational Dermatology

Volumn 2, Issue , 2009, Pages 129-140

  Valentín, Sheila ^a   Morales, Adisbeth ^a   Sánchez, Jorge L ^a   Rivera, Abimael ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Doxycyline; Rosacea; Tetracyclines

Indexed keywords

AZITHROMYCIN; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLARITHROMYCIN; COLESTIPOL; COLESTYRAMINE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ETHINYLESTRADIOL; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; NORETHISTERONE; PHENYTOIN; PLACEBO; RETINOID DERIVATIVE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; WARFARIN;

ABDOMINAL PAIN; ACNE; ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANOSMIA; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; AUTOIMMUNE DISEASE; BLEEDING; BLOATING; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRESS SYNDROME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; EPIGASTRIC BURNING; ESOPHAGITIS; ESOPHAGUS PAIN; ESOPHAGUS ULCER; FIXED DRUG ERUPTION; GASTRITIS; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; HEARTBURN; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INTRACRANIAL HYPERTENSION; LUPUS LIKE SYNDROME; MORNING DOSAGE; MYCOSIS; NAUSEA; NEUTROPENIA; PANCREATITIS; PERIODONTAL DISEASE; PERIODONTITIS; PHOTOSENSITIVITY; PHOTOTOXICITY; PNEUMONIA; PRURITUS; REVIEW; RHINITIS; RHINOPHARYNGITIS; ROSACEA; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SKIN ALLERGY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TASTE DISORDER; THROMBOCYTOPENIA; TOOTH DISCOLORATION; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VAGINAL DRYNESS; VAGINITIS; VOMITING; VULVITIS;

EID: 77953378259     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venerol. 1989;69:419-423.
2. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
4. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
5. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.
6. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999;74:727-729.
7. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265.
8. Maibach H. Second-generation tetracyclines, a dermatologic overview: Clinical uses and pharmacology. Cutis. 1991;48:411-417.
9. Cunha BA, Sibley CM, Ristuccia AM. Review doxycycline. Ther Drug Monit. 1982;4:115-135.
10. Jonas M, Cunha BA. Review minocycline. Ther Drug Monit. 1982;4 137-145.
11. Macdonald H, Kelly RG, Allen ES. Pharmacokinetic studies of minocycline in man. Clin Pharmacol Ther. 1973;14:852.
12. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clinical Pharmacokinet. 1988;15:355-366.
13. Fabre J, Milek E, Kalfopoulos P, et al. The kinetics of tetracyclines in man. Digestive absorption and serum concentrations. Schweiz Med Wochenschr. 1971;101:593-598.
14. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75 Suppl 4:S6-S11.
15. Cullen S, Crounse R. Cutaneous pharmacology of the tetracyclines. J Invest Dermatol. 1965;45:263-268.
16. Pallett AP, Smyth EG. Clinician's guide to antibiotics. Tetracycline. Br J Hosp Med. 1988;40:385-390.
17. Webster G, Del Rosso JQ. Antiinflammatory effects of Tetracyclines. Dermatology Clin. 2007;25:133-135.
18. Esterly NB, Furey NL, Flannagan LE. The effect of antimicrobial agents on chemotaxis. J Invest Dermatol. 1978;70:51-55.
19. Esterly NB, Kovansky JS, Furey NS. Neutrophil chemotaxis in patients with acne receiving tetracyclines. Arch Dermatol. 1984;120: 1308-1313.
20. Gabler WL, Creamer HR. Supression of human neutrophil functions by tetracycline. J Periodontal Res. 1991;26:52-58.
21. Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogs. Clin Exp Immunol. 1979;35:443-446.
22. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P. Inhibition of enzymatic activity of phospholipase A2 by minocycline and doxycycline. Biochem Pharmacol. 1992;P44:1165-1170.
23. Wise RD. Submicrobial doxycycline and rosacea. Comp Ther. 2007;33:78-81.
24. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
25. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
26. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodont Res. 1983;18: 516-526.
27. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-321.
28. Berman B, Zell D. Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis. 2005;75 Suppl 4:S19-S24.
29. Bikowski J. New approaches to rosacea therapy. Skin Aging. 2005;13 Suppl 2:S13-S15.
30. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res. 1998;12:114-118.
31. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.
32. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol. 1994;130:748-752.
33. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad of Sci U S A. 1996;93:14014-14019.
34. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett. 1997;410:259-264.
35. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139 (4):459-464.
36. Thiboutot D. Efficacy and safety of subantmicrobial-dose doxycycline for the treatment of rosacea [poster]. 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, LA. P128. 37. Sanchez J, Somolinos AL, Almodovar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blinded, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53:791-797.
37. Fowler JF. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-645.
38. Del Rosso J, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-576.
39. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: Patient characteristics and follow-up. Ophthalmology. 1997;104:1863-1867.
40. Frucht-Pery J, Chayet AS, Felman ST, Lin S, Brown SI. The effect of doxycycline in ocular rosacea. Am J Ophthalmol. 1989;107:434-435.
41. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88-92.
42. Quaterman MJ, Johnson DW, Abele DC, Lesher JL, Hull DS, Davis LS. Ocular rosacea: Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
43. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosácea. Int J Dermatol. 1997;36:938-946.
44. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284-288.
45. Hersle K, Gisslen H. Minocycline in acne vulgaris: a double-blind study. Curr Ther Res. 1976;19:339-342.
46. Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1988;13:242-244.
47. Laux B. Treatment of acne vulgaris. A comparison of doxycycline versus minocycline. Dermatologist. 1989;40:577-581.
48. Olafsson JH, Gudgierson J, Eggertsdottir GE, Kristjansson F. Doxycycline versus minocycline in the treatment of acne vulgaris: a doubleblind study. J Dermatol Treat. 1989;1:15-17.
49. Del Rosso JQ. Recently approved systemic therapies for acne vulgaris and rosacea. Cutis. 2007;80:113-120.
50. Eady AH, Cove JH, Layton AM. Is antibiotic resitance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4:813-831.
51. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Perio. 2000;71:1472-1483.
52. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995;22:100-109.
53. Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: A review of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74:118-122.
54. Walker C, Webster GF, Del Rosso JQ. A muticenter, double-blind, randomized trial to evaluate the long-term anti-inflammatory doxycycline (40 mg) therapy: results of the lack of effect on bacterial flora [poster]. Foundation for Reaserch and Education in Dermatology, Fall Clinical Dermatology Conference, October 6-9, 2006; Las Vegas, Nevada.
55. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7:571-577.
56. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66:7-13.
57. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133:1224-1230.
58. Smith K, Leyden JJ. Safety of doxycycline and mnocycline: a systematic review. Clin Ther. 2005;27:1329-1342.
59. Segelnick SL, Weinberg MA. Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review. J Am Dent Assoc. 2008;139:581-585.
60. Biller JA, Flores A, Buie T, Mazor S, Katz AJ. Tetracycline-induced esophagitis in adolescent patients. J Pediatr. 1992;120:144-145.
61. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999;74:727-729.
62. Lanza FL. Esophageal ulceration produced by doxycycline Review of the literature and comparison of the injury from doxycycline hyclate and hydrochloride with that from doxycycline monohydrate. Curr Ther Res Clin Exp. 1988;44:475-484.
63. Berger RS. A double-blind, multiple-dose, placebo-controlled, crossover study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol. 1988;28:367-370.
64. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329-1342.
65. Carroll LA, Laumann AE. Doxycycline-induced photo-onycholysis. J Drugs Dermatol. 2003;2:662-663.
66. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline-a dose-related phenomenon. Clin Exp Dermatol. 1993;18:425-427.
67. Simpson MB, Pryzbylik J, Innis B, Denham MA. Hemolytic anemia after tetracycline therapy. N Engl J Med. 1985;312:840-842.
68. Pierog SH, Al-Salihi FL, Cinotti D. Pseudotumor cerebri - a complication of tetracycline treatment of acne. J Adolesc Health Care. 1986;7:139-140.
69. Nelson R, Parker SR. Doxycycline-induced staining of adult teeth: the first reported case. Arch Dermatol. 2006;142:1081-1082.
70. Cac NN, Messingham MJ, Sniezek PJ, Walling HW. Stevens-Johnson syndrome induced by doxycycline. Cutis. 2007;79:119-122.
71. Curley RK, Verbow JL. Stevens-Johnson syndrome due to tetracyclinea case report (doxycycline) and a review of the literature. Clin Exp Dermatol. 1987;12:124-125.
72. Gallais V, Randrianjohanny A, Robineau M, Laroche L. Stevens-Johnson syndrome caused by doxycycline. Presse Med. 1997;26:855.
73. Robles DT, Leonard JL, Compton N, et al. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. Dermatology. 2008;217:23-26.
74. Gul U, Gonul M, Soylu S, Kaya I. Doxycycline-induced fixed drug eruption. J Dermatolog Treat. 2008;19:126-127.
75. Trüeb RM, Burg G. Acute generalized exanthematous pustulosis due to doxycycline. Dermatology. 1993;186:75-78.
76. Khan Durani B, Jappe U. Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. Br J Dermatol. 2002;147:558-562.
77. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today. 2007;43:27-34.
78. Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1988;13:242-244.
79. Allen JC. Minocycline. Ann Intern Med. 1976;85:482-487.
80. Baciewicz AM, Bal BS. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med. 2001;161:1231.
81. Caraco Y, Rubinow A. Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother. 1992;26:1084-1086.
82. Hasan SA. Interaction of doxycycline and warfarin: an enhanced anticoagulant effect. Cornea. 2007;26:742-743.
83. Penning-van Beest FJ, Koerselman J, Herings RM. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost. 2008;6:284-290.
84. Barranco VP. Update on clinically significant drug interactions in dermatology. J Am Acad Dermatol. 2006;54:676-684.
85. Dickinson BD, Altman RD, Nielsen NH, Sterling ML; Council on Scientific Affairs, American Medical Association. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98:853-860.
86. Back DJ, Grimmer SF, Orme ML, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol. 1988;25:527-532.
87. Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril. 1988;49:31S-38S.
88. Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol. 1991;77:416-420.
89. Murphy AA, Zacur HA, Charache P, Burkman RT. The effect of tetracycline on levels of oral contraceptives. Am J Obstet Gynecol. 1991;164:28-33.
90. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46:917-923.
91. FDA.gov (homepage on the Internet). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). (updated 2009 Jan 23;cited 2009 Feb 26) Available from: http://www.fda.gov/cder/orange/default.htm.